Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has announcements × Pemetrexed × Clear all

Phase

Phase 3 20 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Interventions

umbralisib 1 ublituximab 1 relatlimab 1 pembrolizumab 1 palbociclib 1 inavolisib 1 imetelstat 1 Pemetrexed 1 Nivolumab 1 GRN163L peptide 1 Fulvestrant 1 Emapalumab 1 Cisplatin 1 Bendamustine Hydrochloride 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Canadian Cancer Trials Group

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡